To the Editor In the absence of a randomized clinical trial, evaluating underlying market trends and risk is critical to determining whether an intervention resulted in real improvements in quality or costs. Unfortunately, Dr Lee and colleagues1 included neither in an observational study of a value-driven outcomes program that found reduced costs and improved quality in 3 clinical projects.
Weeks WB. Evaluating a Value-Driven Outcomes Program. JAMA. 2016;316(23):2548–2549. doi:10.1001/jama.2016.17827
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: